pembrolizumab


( Last Updated : April 22, 2022)
Generic Name:
pembrolizumab
Project Status:
Pending
Therapeutic Area:
recurrent, or metastatic cervical cancer
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0292-000
Call for patient/clinician input closed:
Tumour Type:
Gynecology

Details


Manufacturer Requested Reimbursement Criteria1:
Pembrolizumab in combination with chemotherapy with or without bevacizumab, for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS=1) as determined by a validated test.
Submission Type:
Initial
Fee Schedule:
Pending
Tumour Type:
Gynecology
Indications:
Pembrolizumab in combination with chemotherapy with or without bevacizumab, for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS=1) as determined by a validated test.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.